HHS Clears Compounding of Six Unapproved Peptides

HHS has cleared a path for state-licensed pharmacies to compound six peptides that have surged in off-label and wellness-market demand, bypassing the formal rulemaking its own scientists said the question deserved. The interim enforcement-discretion policy, announced October 28, 2026, follows by two days this desk's report on a drug-safety coalition's petition asking FDA to block exactly this outcome — and arrives with FDA's Center for Drug Evaluation and Research on record against listing any of the peptides reviewed.

The sequence: a petition, then a policy that overrode it

This desk reported on October 26, 2026 that the Partnership for Safe Medicines (PSM) had filed a citizen petition asking FDA to refrain from any action — rulemaking, bulk-list placement, or enforcement discretion — that would let pharmacies compound seven peptides, including the six now covered by HHS's policy. PSM's petition challenged the legitimacy of the PCAC vote itself, alleging the committee was improperly constituted with members holding undisclosed financial ties to the peptide industry. HHS's October 28 announcement does not appear to resolve or formally respond to that petition; it proceeds on a separate, faster track — enforcement discretion rather than the bulk-list rulemaking PSM's petition was aimed at. The Center for Science in the Public Interest separately wrote FDA calling the PCAC vote procedurally defective.

What enforcement discretion actually does, and doesn't

Enforcement discretion is not approval, and HHS's own policy document says so explicitly. FDA has not found any of the six peptides safe and effective for any use, has not approved them as drugs, and has not added them to the 503A Bulk Drug Substances List through the notice-and-comment rulemaking that would normally be required. What has changed is practical risk: HHS and FDA are stating in advance that they will decline to pursue enforcement against qualifying state-licensed compounders who follow the policy's conditions, while that rulemaking continues. For a compounding pharmacy that has treated these substances as a legal grey area, that is a meaningful shift in day-to-day compliance posture — even though the underlying legal status of the peptides has not formally changed.

Why RA/QA teams should track this

• 503A compounding pharmacies: the conditions matter as much as the clearance — an FDA-registered, CGMP-compliant bulk source, certificate of analysis and identity verification, patient-specific prescriptions, and adverse-event/product-quality reporting are now the operative compliance bar for these six peptides, not an open question.
• 503B outsourcing facilities: this policy does not apply to you. Compounding any of these six peptides at a 503B facility remains outside its protection.
• Drug and device manufacturers with competing or adjacent products: enforcement discretion, reached without the rulemaking record or clinical-trial data an approval would require, is a materially different competitive landscape than a formal bulk-list rule — and one that can be withdrawn by the next policy memo, unlike a finalized rule.
• Anyone relying on FDA advisory-committee outcomes as a signal: HHS followed PCAC's 6-of-7 vote over its own center's scientific recommendation for six of seven peptides — a data point for how much weight an advisory vote carries against staff-level review when the two diverge.

What is not yet settled

The interim policy is explicitly a bridge, not an endpoint: formal rulemaking on permanent 503A Bulk Drug Substances List status for these peptides continues separately, and HHS has not said when that rulemaking will conclude. PSM's citizen petition remains pending and unresolved as of this writing, and Regulatory News found no indication HHS addressed its procedural allegations against PCAC's composition in this announcement. Emideltide's exclusion from the policy, while the other six were cleared, is also unexplained in the sourcing available; readers should treat that as an open question pending further FDA or HHS comment.

Frequently asked questions

What did HHS announce on 28 October 2026?

An interim enforcement-discretion policy for compounding six peptides — BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon — under Section 503A, while formal bulk-list rulemaking continues. Federal Register document 2026-22192, docket HHS-OASH-2026-0496.

Is this the same as FDA approval?

No. HHS's policy explicitly states it is not an FDA approval of any of the six peptides.

Why did HHS go ahead despite FDA's own reviewers opposing it?

FDA's Pharmacy Compounding Advisory Committee voted 6 of 7 in favor in July 2026, overriding CDER staff, who had recommended against listing any of the seven peptides reviewed.

What conditions apply to compounders relying on this policy?

An FDA-registered, CGMP-compliant bulk source with certificate of analysis; patient-specific prescriptions; mandatory adverse-event and product-quality reporting; some dosage-form/route limits; and no extension to 503B outsourcing facilities.